SGHT · Sight Sciences, Inc.
$9.04
-0.33 (-3.47%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$491.94M
Shares
55.09M
Volume · Oct 1
195.12K
Avg daily vol (3M)
241.46K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.36
Open$9.39
Day$9.19–9.58
52W close$3.20–9.36
Avg vol 30d234K
Short int1.3M · 2.3% float · 8.5d
Short vol44%
Last earningsAug 5, 2026
DataJul 2021–Sep 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 5 wks
filed Aug 5, 2026
call held Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$83.38M
Trailing 12 months
Net income (TTM)
−$29.76M
Trailing 12 months
Revenue growth YoY
+19.5%
Year over year
Operating margin
-33.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$38.98M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+5.2%
Year over year · more shares
Price change (1Y)
+172.1%
Trailing year
Short interest
2.3%
Latest settlement · 8.5 days to cover
AI Brief
Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26
TL;DR. Sight Sciences posted 20% Q2 revenue growth, raised full-year 2026 revenue guidance to $88–$92M and lowered adjusted operating expense guidance to $92–$94M, driven by record Interventional Dry Eye sales and a fourth consecutive quarter of Interventional Glaucoma growth.
Bullish
- + Total Q2 revenue grew 20% year-over-year to $23.4M, the strongest growth rate in three years
- + Interventional Dry Eye achieved record revenue of $2.7M, nearly doubling sequentially and up 704% year-over-year
- + Raised full-year 2026 revenue guidance to $88–$92M, including raising IDE guidance to $9–$11M from $6–$8M
- + Interventional Glaucoma posted its fourth consecutive quarter of YoY growth at $20.7M, up 8%, with a record number of active accounts
- + Reduced full-year 2026 adjusted operating expense guidance to $92–$94M from $93–$96M while net loss improved 63%
- + IDE covered lives increased to ~14.5M from ~10.4M and Aetna added ~25M covered lives for IG, completing coverage across all major national payers
Bearish
- − Q3 2026 IG revenue is expected to grow only in the mid-single digits against a tougher prior-year comparison and historical seasonality
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+59%
above
Price vs 50-day avg
+23%
above
RSI (14)
77
overbought
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+14%
trailing
6-month return
+167%
trailing
YTD return
+18%
this year
Relative strength
+155%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $6 — 50d above 200d
Institutional flow
Distributing
-2% holders QoQ · +15 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.27% of float · ▲ +2.4% MoM · 8.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
112 holders — near 3-yr high, broad support
Squeeze score
72
high risk · 0–100
Fundamentals
Revenue growth
−3%
Y/Y
Gross margin
86%
expanding
EPS growth
+28%
Y/Y
Free cash flow
$-29.9M
Balance sheet
$51.7M
net cash
Quant / Vol
risk profile
Volatility
84%
annualized · 1-yr
Max drawdown
−62%
past year
ATR
4.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
Interventional Glaucoma revenue
· full year 2026
Initiated
$79M – $81M
Guided vs delivered
· last 1 settled
Full-year 2021 revenue
full-year 2021
guided $46M – $48M
$48.96M
Beat +4.2%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+59%
Bullish
Price vs 50-day avg
+23%
Bullish
RSI (14)
77
Bearish
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $8 › 200d $6 — 50d above 200d
Institutional flow
Distributing
-2% holders QoQ · +15 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.27% of float · ▲ +2.4% MoM · 8.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
112 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $9 · 100%
Range high $9
vs 200-day avg +59%
vs 50-day avg +23%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SGHT
this stock
Sight Sciences, Inc.
|
$491.94M | +18.0% | -3.1% | — | 2.3% |
|
ABT
Abbott Laboratories
|
$174.90B | -21.1% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.2% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.2% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SGHT | +10.1% | +14.3% | +167.4% | +10.1% | +18.0% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +10.8% | +14.2% | +155.3% | +10.7% | +6.2% |